Aims and Scope of Annals of the Rheumatic Diseases
The Annals of the Rheumatic Diseases is a peer-reviewed medical journal. It is co-owned by the BMJ Group and the European League Against Rheumatism and covers all aspects of rheumatology, including musculoskeletal conditions, arthritis, and connective tissue diseases. The journal publishes basic, clinical, and translational research and abstracts from conferences. The journal was established in 1939. It is available online by subscription and archived editions of the journal (older than one year) are available free of charge. Each issue, the editor-in-chief selects a paper to be published open access as an "Editors Choice". The editor-in-chief is Josef Smolen. Less
Key Metrics
CiteScore 

28.5
Eigenfactor 

0.05 - 0.1
H-Index 

272
Impact Factor 

>= 25
Scite Index 

0.88 5-Year SI

SJR 

Q1Immunology

SNIP 

5.22
Recommended pre-submission checks
Powered by 

Topics Covered on Annals of the Rheumatic Diseases
Annals of the Rheumatic Diseases Journal Specifications
| Overview | |
| Publisher | BMJ PUBLISHING GROUP |
| Language | English |
| Frequency | Monthly |
| General Details | |
| Language | English |
| Frequency | Monthly |
| Publication Start Year | 1935 |
| Publisher URL | Visit website |
| Website URL | Visit website |
View less
Planning to publish in Annals of the Rheumatic Diseases ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations

Recently Published Papers in Annals of the Rheumatic Diseases
Effects of air pollution on disease activity in patients with rheumatoid arthritis.
- 21 Jun 2028
- Annals of the rheumatic diseases
Development and validation of minimal disease activity, disease flare, and minimal clinically important difference for children with chronic nonbacterial osteomyelitis using a consensus and data-driven approach.
- 8 Aug 2026
- Annals of the rheumatic diseases
Efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with active psoriatic arthritis: 52-week results from the randomised, double-blind, placebo-controlled phase 3 POETYK PsA-1 trial.
- 6 Aug 2026
- Annals of the rheumatic diseases
EXTL3 dysfunction identified as a driver of aberrant bone development in severe familial ankylosing spondylitis.
- 6 Aug 2026
- Annals of the rheumatic diseases
Response to correspondence on 'Progression from symptom onset to rheumatoid arthritis: is the trajectory similar in anticitrullinated protein antibody-positive and -negative disease? A comparative longitudinal study'.
- 6 Aug 2026
- Annals of the rheumatic diseases
Air pollution and rheumatoid arthritis disease activity: linking pathogenesis and progression.
- 5 Aug 2026
- Annals of the rheumatic diseases
Effects of air pollution on disease activity in patients with rheumatoid arthritis.
- 21 Jun 2028
- Annals of the rheumatic diseases
Development and validation of minimal disease activity, disease flare, and minimal clinically important difference for children with chronic nonbacterial osteomyelitis using a consensus and data-driven approach.
- 8 Aug 2026
- Annals of the rheumatic diseases
Efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with active psoriatic arthritis: 52-week results from the randomised, double-blind, placebo-controlled phase 3 POETYK PsA-1 trial.
- 6 Aug 2026
- Annals of the rheumatic diseases
EXTL3 dysfunction identified as a driver of aberrant bone development in severe familial ankylosing spondylitis.
- 6 Aug 2026
- Annals of the rheumatic diseases
Response to correspondence on 'Progression from symptom onset to rheumatoid arthritis: is the trajectory similar in anticitrullinated protein antibody-positive and -negative disease? A comparative longitudinal study'.
- 6 Aug 2026
- Annals of the rheumatic diseases
Air pollution and rheumatoid arthritis disease activity: linking pathogenesis and progression.
- 5 Aug 2026
- Annals of the rheumatic diseases